X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs BIOCON LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS BIOCON LTD NOVARTIS/
BIOCON LTD
 
P/E (TTM) x 385.2 50.3 765.2% View Chart
P/BV x 33.9 7.3 462.3% View Chart
Dividend Yield % 1.3 0.2 854.0%  

Financials

 NOVARTIS   BIOCON LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
BIOCON LTD
Mar-18
NOVARTIS/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs7581,188 63.8%   
Low Rs579305 189.8%   
Sales per share (Unadj.) Rs228.468.7 332.3%  
Earnings per share (Unadj.) Rs31.77.6 420.3%  
Cash flow per share (Unadj.) Rs32.814.0 234.5%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.50.1 1,116.7%  
Book value per share (Unadj.) Rs297.186.3 344.1%  
Shares outstanding (eoy) m24.69600.00 4.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.910.9 26.9%   
Avg P/E ratio x21.198.9 21.3%  
P/CF ratio (eoy) x20.453.4 38.2%  
Price / Book Value ratio x2.28.6 26.0%  
Dividend payout %31.513.2 237.9%   
Avg Mkt Cap Rs m16,505447,900 3.7%   
No. of employees `0000.76.1 10.9%   
Total wages/salary Rs m1,4459,311 15.5%   
Avg. sales/employee Rs Th8,441.36,705.8 125.9%   
Avg. wages/employee Rs Th2,163.61,514.2 142.9%   
Avg. net profit/employee Rs Th1,173.1736.9 159.2%   
INCOME DATA
Net Sales Rs m5,63941,234 13.7%  
Other income Rs m1,7182,062 83.3%   
Total revenues Rs m7,35743,296 17.0%   
Gross profit Rs m-638,291 -0.8%  
Depreciation Rs m253,851 0.7%   
Interest Rs m55615 9.0%   
Profit before tax Rs m1,5755,887 26.8%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,569 50.5%   
Profit after tax Rs m7844,531 17.3%  
Gross profit margin %-1.120.1 -5.5%  
Effective tax rate %50.326.7 188.6%   
Net profit margin %13.911.0 126.5%  
BALANCE SHEET DATA
Current assets Rs m9,52241,486 23.0%   
Current liabilities Rs m3,29621,413 15.4%   
Net working cap to sales %110.448.7 226.8%  
Current ratio x2.91.9 149.1%  
Inventory Days Days3764 57.2%  
Debtors Days Days2894 30.2%  
Net fixed assets Rs m4650,661 0.1%   
Share capital Rs m1233,000 4.1%   
"Free" reserves Rs m7,21348,808 14.8%   
Net worth Rs m7,33651,808 14.2%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m11,10599,897 11.1%  
Interest coverage x29.510.6 278.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.4 123.0%   
Return on assets %7.65.2 146.6%  
Return on equity %10.78.7 122.1%  
Return on capital %22.29.6 230.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6112,058 0.5%   
Fx outflow Rs m3,6307,348 49.4%   
Net fx Rs m-3,5704,710 -75.8%   
CASH FLOW
From Operations Rs m1,6106,621 24.3%  
From Investments Rs m687-6,840 -10.0%  
From Financial Activity Rs m-2,677-2,397 111.7%  
Net Cashflow Rs m-380-2,612 14.5%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 2.0 8.4 23.8%  
FIIs % 1.6 10.7 15.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.9 108.0%  
Shareholders   41,647 109,995 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   WYETH LTD  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 17, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - FDC LTD. COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS